Embecta Corp. (EMBC) to Issue Quarterly Dividend of $0.15 on March 17th

Embecta Corp. (NASDAQ:EMBC) declared a quarterly dividend on Thursday, February 5th. Investors of record on Friday, February 27th will be given a dividend of 0.15 per share on Tuesday, March 17th. This represents a c) dividend on an annualized basis and a dividend yield of 5.5%. The ex-dividend date is Friday, February 27th.

Embecta has a payout ratio of 21.0% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Embecta to earn $3.07 per share next year, which means the company should continue to be able to cover its $0.60 annual dividend with an expected future payout ratio of 19.5%.

Embecta Price Performance

Shares of Embecta stock opened at $10.86 on Friday. The business has a fifty day simple moving average of $11.76 and a two-hundred day simple moving average of $12.96. Embecta has a 1 year low of $9.20 and a 1 year high of $18.07. The company has a market capitalization of $643.02 million, a price-to-earnings ratio of 4.58 and a beta of 1.11.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Thursday, February 5th. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.67 by $0.04. The firm had revenue of $261.20 million for the quarter, compared to the consensus estimate of $258.07 million. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. The company’s quarterly revenue was down .3% on a year-over-year basis. During the same period in the previous year, the company earned $0.65 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. As a group, equities analysts anticipate that Embecta will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Wall Street Zen cut shares of Embecta from a “strong-buy” rating to a “buy” rating in a report on Saturday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. Finally, BTIG Research reissued a “buy” rating and set a $25.00 price target on shares of Embecta in a report on Friday. One research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Embecta currently has an average rating of “Hold” and a consensus price target of $18.50.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.